Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
5 of 5 strong
The short version
The company targets a top-line growth of 25% to 30% annually for FY '27 and the next few years. The company targets a top-line growth of 25% to 30% annually over the next few years.
From Fredun Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a top-line growth of 25% to 30% annually for FY '27 and the next few years.
- Growth has been steady with a 32% CAGR over the last 19 years, with no degrowth year.
- New age businesses like Pet Care, Mobility, and Nutraceuticals are growing rapidly at 40% to 50% CAGR from smaller bases.
- Vintage pharmaceutical business is growing steadily at 10% to 15%.
- Working capital and cash flows have improved, supporting growth without financial strain.
- EBITDA margins expected to improve over the next 8-9 quarters with a potential spike in profitability as new products saturate demographic reach within 2.5 to 3 years.
2 more points from Fredun Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fredun Pharmaceuticals is actively expanding manufacturing capacity, adding 12 to 13 packing lines by the end of September 2026.
- A new wing is being constructed within their existing plant to further enhance production capabilities.
- The company plans to become one of the top 3-4 manufacturing plants in capacity in the country within the next 2.5 years, leveraging its cluster of 4 plants at one location.
- Facilities are being set up for functional foods and planning to manufacture various wet food products.
- Investment in manufacturing infrastructure took INR400-500 crores over past decades, with ongoing optimization and utilization as a key asset.
2 more points from Fredun Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals maintains a steady orderbook with 6 to 7 months of orders always in hand.
- Currently, the company has confirmed orders upwards of INR 320 crores to INR 330 crores in hand.
- This robust order pipeline allows the company to give orders ahead to its suppliers, ensuring supply chain stability amid geopolitical changes.
2 more points from Fredun Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Guj. Themis Bio. (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fredun Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q4 FY26 results?
The company targets a top-line growth of 25% to 30% annually for FY '27 and the next few years. The company targets a top-line growth of 25% to 30% annually over the next few years.
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 57.6 with a market cap of ₹2,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Fredun Pharmaceuticals is actively expanding manufacturing capacity, adding 12 to 13 packing lines by the end of September 2026.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.